The agreement ends litigation between the Swiss company and the estate of Henrietta Lacks, which filed a lawsuit in federal court in Baltimore against Novartis and Viatris in August 2024. The family ...

Ashley Woerner, SVP of account services at Synapse, adds that Rhapsido gained wider recognition as a brand thanks to the ...

Novartis ( NVS 0.66%) is a major Swiss drug company with a market capitalization of over $300 billion. Its focus areas are ...

Outside the drug’s current urticaria niche, Novartis is also developing remibrutinib in myasthenia gravis and multiple ...

Unnatural Products is proving to be a natural at securing partnerships, this time linking up with Novartis in a deal that could garner up to $1.7 billion in biobucks.

The head of biomedical research at Novartis spoke with STAT about AI, pruning the pipeline, and a potential blockbuster.

Four years after he resigned as chief medical officer at Novartis in the wake of a restructuring at the Big Pharma, John Tsai ...

Feb 20 (Reuters) - Swiss drugmaker Novartis will sell its entire 70.68% stake in its listed Indian unit to a private ...

Phase III program in food allergy (FA) planned for H2 2026 ...

In the real-world, Pluvicto showed 13.5 months median PFS in chemo-naïve patients with PSMA-positive mCRPCReal-world evidence showed Pluvicto achieved longer PFS when initiated after one ARPI instead ...

ROME, Georgia, Feb 19 (Reuters) - U.S. President Donald Trump said he met Vas Narasimhan, the chief executive officer of ...